Upstream Bio, Inc. (UPB) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $7.51: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and... Read more
Sell if holding. Engine safety override at $7.51: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 77. Score 5.6/10, moderate confidence.
Passes 7/10 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 32d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $7.51: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 77. Prior stop was $6.98. Score 5.6/10, moderate confidence.
Take-profit target: $7.62 (+1.5% upside). Prior stop was $6.98. Stop-loss: $6.98.
DATA_ISSUE: analyst_target_implausible (raw $38.25 vs price $7.51 — ratio 5.1×). Rejected, falling back to technical TP.; Quality below floor (3.5 < 4.0); Value-trap signals (3/5): Margin compression (op margin -39.8%), Material insider selling (3 sells, 0.04% of cap), Negative free cash flow.
Upstream Bio, Inc. trades at a P/E of N/A (forward -2.6). TrendMatrix value score: 5.0/10. Verdict: Sell.
12 analysts cover UPB with a consensus score of 4.0/5. Average price target: $38.
What does Upstream Bio, Inc. do?Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on...
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.